by Progress in Diagnostic Technology Expected to Improve HIV/AIDS Detection
Diagnostic technology has evolved at a rapid pace over the past decade, owing to significant breakthroughs in research and development. Within the HIV/AIDS immunoassay diagnostics market landscape, the demand for automated clinical laboratory has paved the way for efficient and reliable antibodies and antigen identification techniques. Despite significant progress, the human immunodeficiency virus (HIV) continues to be a major global health problem and a medical challenge. Some of the most effective and critical HIV management strategies include antiretroviral therapy (ART) initiation, early diagnosis, and assessment of the viral load.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111754
HIV diagnostic tests offer two solutions – detection of virus molecules (p24 antigen and HIV RNA) and/or different antibodies to the virus. HIV/AIDS immunoassays, in particular, are used to detect antibodies and p24 antigen. Due to the growing need to curb HIV/AIDS and other types of HIV infections, the demand for efficient diagnostic techniques has increased significantly worldwide. The global HIV/AIDS immunoassay diagnostics market is expected to expand from ~US$ 570 Mn in 2019 to a value of ~US$ 870 Mn by 2027.
Growing Focus on Improving Effectiveness of HIV Diagnostics – A Rising Trend
Around 38 million individuals across the world had HIV in 2018 of which, approximately 36 million were adults. Furthermore, ~1.7 million new HIV cases were registered in 2018 and the numbers continue to grow, especially in the sub-Saharan region and low-income economies. Key participants involved in the HIV/AIDS immunoassay diagnostics market are focusing on simplifying and improving the effectiveness of HIV diagnostics.
Antibody screening tests including the enzyme linked immunosorbent assay (ELISA) are predominantly used to measure antibodies in blood. This test is generally the first test ordered by healthcare professionals to detect HIV antigens in the blood. Traditionally, enzyme-linked immunosorbent assays are complex, expensive, and often require a skilled professional. However, as ELISA is easier and safer than radioimmunoassay (RIA); its adoption will continue to grow at a steady pace over the forecast period (2019-2027). Thus, the ELISA segment is projected to create an incremental opportunity of ~US$ 112 Mn between the stipulated timeframe of the study. The diagnostic results using ELISA could take a few days, which has led to the need for rapid testing techniques.
Get a glimpse of the in-depth analysis through our Report Brochure
Despite steady growth of the ELISA segment, the chemiluminescent immunoassay segment (CLIA) segment is expected to hold a larger share of the HIV/AIDS immunoassay diagnostics market, in terms of value. By the end of 2027, the CLIA segment is likely to account for ~48% of the total share of the HIV/AIDS immunoassay diagnostics market and witness a CAGR of ~6% during the forecast period. Over the past few years, CLIA has gained significant popularity in various sectors, including clinical diagnosis, life sciences, pharmaceutical analysis, and environmental monitoring, among others due to factors such as optimum specificity, easy-to-use equipment, wider linear range, and high sensitivity. Techniques based on chemiluminescent are increasingly being used for clinical analysis and several biomedical research activities.
Market Players to Focus on Efficiency and Expanding Product Portfolio
Presently, major players operating in the global HIV/AIDS immunoassay diagnostics market are striving to offer effective, reliable, cost-effective HIV/AIDS immunoassay diagnostics. In addition, increasing prevalence of HIV/AIDS and HIV infections worldwide have prompted market participants to provide new and improved HIV testing technologies. Companies are focusing on improving patient outcomes and minimizing disease transmission, which requires reliable and accurate clinical laboratory testing. For instance, Siemens Healthineers launched the Atellica ® IM and ADVIA Centaur ® HIV Combo to improve the detection of HIV infections. The entry of new technologies, including the third-generation enzyme immunoassay, which detects IgM and IgG antibodies and fourth-generation enzyme immunoassay that detect HIV p24 and HIV antibodies, are some of the most recent groundbreaking developments in the global HIV/AIDS immunoassay market.
Moreover, product development is likely to fuel the global HIV/AIDS immunoassay market, as companies are seeking approvals from the U.S. FDA. For instance, Shenzen New Industries Biomedical Engineering Co., Ltd (SNIBE) became the first China-based company in the HIV/AIDS immunoassay diagnostics market to receive the approval from the U.S. FDA for the newly developed automated immunoassay analyzer.
Analysts’ Viewpoint
Companies operating in the HIV/AIDS immunoassay diagnostics market should focus on improving the effectiveness of their HIV diagnosis techniques. In addition, clinical and laboratory trials of newer technologies will play an imperative role in driving the growth of the HIV/AIDS immunoassay diagnostics market. Despite a healthy competition from the ELISA segment, CLIA is likely to retain its dominance, in terms of adoption, during the forecast period. Developments in the CLIA technology, including the flow-injection CLIA technology, will address problems associated with existing alternatives.
Global HIV/AIDS Immunoassay Diagnostics Market: Overview
This report analyzes the current scenario and future prospects of the global HIV/AIDS immunoassay diagnostics market. Rise in prevalence of sexually transmitted diseases, HIV infected population, and development of new treatment modes are key factors projected to drive the global HIV/AIDS immunoassay diagnostics market during the forecast period.
The report provides an elaborate executive summary, including a snapshot of various segments of the HIV/AIDS immunoassay diagnostics market. It also provides elaborate information and data analysis of the global HIV/AIDS immunoassay diagnostics market with regard to segments based on technology, product, end user, and region.
The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global HIV/AIDS immunoassay diagnostics market
The report also includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the HIV/AIDS immunoassay diagnostics market
The report on the global HIV/AIDS immunoassay diagnostics market offers market attractiveness analysis of regions and segments
The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global HIV/AIDS immunoassay diagnostics market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global HIV/AIDS immunoassay diagnostics market.
Global HIV/AIDS Immunoassay Diagnostics Market: Key Segments
In terms of product, the global HIV/AIDS immunoassay diagnostics market has been classified into analyzers and kits & reagents. The kits & reagents segment held a major share of the global HIV/AIDS immunoassay diagnostics market in 2018 and the trend is anticipated to continue during the forecast period.
Based on technology, the global HIV/AIDS immunoassay diagnostics market has been segmented into enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and others (immunofluorescent assay (IFA), radioimmunoassay (RIA), and enzyme-linked fluorescent assay (ELFA)). The chemiluminescence immunoassay (CLIA) segment accounted for a majority of the market share in 2018.
In terms of end user, the global HIV/AIDS immunoassay diagnostics market has been categorized into hospitals, diagnostic laboratories, blood banks, and others
The market value and forecast for each of these segments have been provided from 2017 to 2027. The CAGRs of respective segments have also been provided from 2019 to 2027, considering 2018 as the base year.
Global HIV/AIDS Immunoassay Diagnostics Market: Regional Outlook
In terms of region, the global HIV/AIDS immunoassay diagnostics market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
The HIV/AIDS immunoassay diagnostics market report provides value and forecast for each region and country/sub-region from 2017 to 2027. The CAGRs for each of these regions and countries have also been provided for the forecast period from 2019 to 2027. The HIV/AIDS immunoassay diagnostics market study also covers the competitive scenario in these regions.
Companies Mentioned in Report
Key players in the global HIV/AIDS immunoassay diagnostics market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
Major companies profiled in the global HIV/AIDS immunoassay diagnostics market report are
- F. Hoffmann-La Roche Ltd
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- DiaSorin S.p.A.
- Abbott Laboratories
- Ortho Clinical Diagnostics (a part of Carlyle Group)
- Shenzhen New Industries Biomedical Engineering Co., Ltd.
- bioMérieux SA
- Fujirebio (Miraca Group)
Key Questions Answered in HIV/AIDS Immunoassay Diagnostics Market Report
- What are the major drivers, restraints, and opportunities in the global HIV/AIDS immunoassay diagnostics market?
- What will be the revenue share projections of key segments in the global HIV/AIDS immunoassay diagnostics market during the forecast period?
- Which segment is likely to lead the global HIV/AIDS immunoassay diagnostics market in terms of revenue by 2027?
- How mergers & acquisitions among players are widening the scope for the global HIV/AIDS immunoassay diagnostics market?
- Which are the leading companies in the global HIV/AIDS immunoassay diagnostics market?
Global HIV/AIDS Immunoassay Diagnostics Market – Segmentation
Product
- Analyzers
- Kits & Reagents
Technology
- Enzyme-linked Immunosorbent Assay (ELISA)
- Chemiluminescence Immunoassay (CLIA)
- Others
End User
- Hospitals
- Diagnostic Laboratories
- Blood Banks
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111754/2900
